SCHEMBL5361102

SCHEMBL5361102

Cc1ccc(O)c(C=NNC(=S)Nc2cccc(C(=O)O)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.65
GAA P10253 8/20 0.65
KDM4E B2RXH2 8/20 0.65
SMN1; SMN2 Q16637 7/20 0.65
ALDH1A1 P00352 9/20 0.64
RAB9A P51151 7/20 0.64
NPC1 O15118 6/20 0.64
THRB P10828 2/20 0.64
HPGD P15428 2/20 0.64
MAPK1 P28482 5/20 0.60
STAT3 P40763 1/20 0.60
STAT1 P42224 1/20 0.60
KMT2A Q03164 7/20 0.59
MEN1 O00255 5/20 0.59
POLB P06746 2/20 0.59
L3MBTL1 Q9Y468 3/20 0.58
MITF O75030 1/20 0.58
LMNA P02545 2/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361099 1.00 MAPT (0.65) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5375954 0.87 MAPT (0.63) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5375949 0.87 MAPT (0.63) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5369608 0.83 GAA (0.76) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5369604 0.83 GAA (0.76) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5366770 0.80 MAPT (0.62) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5366765 0.80 MAPT (0.62) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5357695 0.79 GAA (0.69) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5357700 0.79 GAA (0.69) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5373013 0.79 NCOA1 (0.55) MAPTGAAKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885GAA 3120/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.